Heather Calhoun
Medical · Brookville, PANPI 1649303041
Payments from drug & device makers
Across 267 payments — averaging $16.34 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$717
- Novo Nordisk$660
- Lilly USA, LLC$465
- Pfizer$464
- GSK$367
- Amgen$323
- plus $1K from 22 others
What the payments were for
- Food & beverage$4,362100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie | 49 | $717 |
| Novo Nordisk | 45 | $660 |
| Lilly USA, LLC | 25 | $465 |
| Pfizer | 30 | $464 |
| GSK | 22 | $367 |
| Amgen | 18 | $323 |
| Boehringer Ingelheim | 14 | $230 |
| Exact Sciences | 8 | $148 |
| Phathom Pharmaceuticals, Inc. | 8 | $142 |
| Novartis | 6 | $106 |
| AstraZeneca | 6 | $96 |
| E.r. Squibb & Sons, L.L.C. | 6 | $88 |
| Abbott | 5 | $83 |
| Otsuka America Pharmaceutical, Inc. | 4 | $72 |
| Astellas Pharma US Inc | 3 | $70 |
| Bayer | 4 | $69 |
| ZOLL Services LLC (a/k/a ZOLL Lifecor Corp) | 2 | $50 |
| Daiichi Sankyo Inc. | 2 | $46 |
| Inari Medical, Inc. | 1 | $26 |
| Impel Pharmaceuticals LLC | 1 | $23 |
| Ironwood Pharmaceuticals, Inc | 1 | $18 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 1 | $17 |
| Kowa Pharmaceuticals America, Inc. | 1 | $16 |
| Merck | 1 | $15 |
| Dexcom, Inc. | 1 | $15 |
| Biohaven Pharmaceutical Holding Company Ltd. | 1 | $13 |
| GE HealthCare | 1 | $13 |
| Sanofi-aventis U.S. LLC | 1 | $13 |
How this compares
$4,362 in reported general payments places this provider in the 85th percentile of 2,594 medical providers in Pennsylvania.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| JardianceEmpagliflozin | 162 | $147,097 |
| OzempicSemaglutide | 137 | $133,054 |
| EliquisApixaban | 138 | $112,235 |
| XareltoRivaroxaban | 116 | $94,093 |
| RybelsusSemaglutide | 41 | $58,000 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 56 | $57,977 |
| ProliaDenosumab | 28 | $45,503 |
| JanuviaSitagliptin Phosphate | 60 | $43,179 |
| FarxigaDapagliflozin Propanediol | 55 | $41,267 |
| MounjaroTirzepatide | 34 | $34,495 |
| TradjentaLinagliptin | 55 | $32,706 |
| TrulicityDulaglutide | 35 | $32,600 |
| MyrbetriqMirabegron | 35 | $24,655 |
| RexultiBrexpiprazole | 15 | $21,231 |
| EntrestoSacubitril/Valsartan | 21 | $16,695 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Novo NordiskOzempic, Rybelsus | $660 | $191,055178 claims |
| Boehringer IngelheimJardiance, Tradjenta, Spiriva Respimat | $230 | $187,458231 claims |
| PfizerEliquis | $464 | $112,235138 claims |
| GSKTrelegy Ellipta, Breo Ellipta, Anoro Ellipta, Arnuity Ellipta | $367 | $92,357121 claims |
| Lilly USA, LLCMounjaro, Trulicity | $465 | $67,09569 claims |
| AmgenProlia | $323 | $45,50328 claims |
| MerckJanuvia | $15 | $43,17960 claims |
| AstraZenecaFarxiga | $96 | $41,26755 claims |
| Astellas Pharma US IncMyrbetriq | $70 | $24,65535 claims |
| Otsuka America Pharmaceutical, Inc.Rexulti | $72 | $21,23115 claims |
| NovartisEntresto | $106 | $16,69521 claims |
| AbbVieLinzess | $717 | $12,77424 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 2,594 medical providers in Pennsylvania.
Other medical in Brookville
- Jacqueline KernaghanSpringfield$427K
- Drew SodaNew Hope$220K
- Angela KapalkoPhiladelphia$123K
- Linda PerryPhiladelphia$123K
- Cory DavidsonErie$119K
- Shelley SassamanTamaqua$90K
- Meghan HoffnerBethlehem$86K
- Thomas IacovoniDanville$72K
- Scott CoxWynnewood$66K
- Sarah SmithPhiladelphia$65K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.